These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10991964)

  • 21. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study.
    Aronson D; Verbalis JG; Mueller M; Krum H;
    Eur J Heart Fail; 2011 Mar; 13(3):327-36. PubMed ID: 21199833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal endothelin system in rats with liver cirrhosis.
    Hocher B; Zart R; Diekmann F; Gross P; Distler A; Bauer C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S434-5. PubMed ID: 8587436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Jiménez W; Angeli P; Leivas A; Clària J; Graziotto A; Arroyo V; Rivera F; Rodés J
    Gastroenterology; 1995 Jul; 109(1):217-23. PubMed ID: 7797019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
    Takeuchi M; Lee JD; Shimizu H; Ueda T
    Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
    Ginès P; Guevara M
    Hepatology; 2008 Sep; 48(3):1002-10. PubMed ID: 18671303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Aquaretic agents].
    Jiménez W
    Nefrologia; 2002; 22 Suppl 5():52-5. PubMed ID: 12107918
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency.
    Wang W; Li C; Summer SN; Falk S; Cadnapaphornchai MA; Chen YC; Schrier RW
    Am J Physiol Renal Physiol; 2006 May; 290(5):F1135-42. PubMed ID: 16352742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F; Blei AT; Blendis LM; Thuluvath PJ
    Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
    Gerbes AL; Gülberg V; Ginès P; Decaux G; Gross P; Gandjini H; Djian J;
    Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
    Wong F; Gines P; Watson H; Horsmans Y; Angeli P; Gow P; Minini P; Bernardi M
    J Hepatol; 2010 Aug; 53(2):283-90. PubMed ID: 20541828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy.
    Schrier RW; Fassett RG; Ohara M; Martin PY
    Proc Assoc Am Physicians; 1998; 110(5):407-11. PubMed ID: 9756091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C; Pistrosch F; Herbrig K; Gross P
    Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
    Fernández-Varo G; Oró D; Cable EE; Reichenbach V; Carvajal S; de la Presa BG; Wiśniewski K; Ginés P; Harris G; Jiménez W
    Hepatology; 2016 Jan; 63(1):207-16. PubMed ID: 26403564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats.
    Lacour C; Galindo G; Canals F; Segondy D; Cazaubon C; Serradeil-Le Gal C; Roccon A; Nisato D
    Eur J Pharmacol; 2000 Apr; 394(1):131-8. PubMed ID: 10771045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
    J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Renal effects of the chronic inhibition of nitric oxide synthesis in cirrhotic rats with ascites].
    Ortiz MC; Fortepiani LA; Martínez-Salgado C; Eleno N; Atucha NM; López-Novoa JM; García-Estañ J
    Nefrologia; 2001; 21(6):556-64. PubMed ID: 11881425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR
    Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
    Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
    Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.